{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:15:21Z","timestamp":1786976121959,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd014741","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000}}],"reference-count":376,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014741.pub2","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T08:00:28Z","timestamp":1726732828000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases"],"prefix":"10.1002","volume":"2024","author":[{"given":"Arturo J","family":"Mart\u00ed-Carvajal","sequence":"additional","affiliation":[{"name":"Universidad UTE, Facultad de Ciencias de la Salud Eugenio Espejo, Centro Asociado Cochrane Ecuador, Centro de Investigaci\u00f3n en Salud P\u00fablica y Epidemiolog\u00eda Cl\u00ednica (CISPEC); Quito Ecuador"},{"name":"Facultad de Medicina (Centro Cochrane Madrid); Universidad Francisco de Vitoria; Madrid Spain"},{"name":"C\u00e1tedra Rectoral de Medicina Basada en la Evidencia; Universidad de Carabobo; Valencia  Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario A","family":"Gemmato-Valecillos","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai\/ NYCHH Elmhurst Hospital Center; 79-01 Broadway, Elmhurst, New York 11373 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Monge Mart\u00edn","sequence":"additional","affiliation":[{"name":"Faculty of Medicine; Universidad Francisco de Vitoria; Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Dayer","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute; Mater Private Network; Dublin Ireland"},{"name":"Faculty of Health; University of Plymouth; Plymouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Alegr\u00eda-Barrero","sequence":"additional","affiliation":[{"name":"Faculty of Medicine; Universidad Francisco de Vitoria; Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Bautista","family":"De Sanctis","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine; Palacky University, Faculty of Medicine and Dentistry; Olomouc Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Marcos","family":"Parise Vasco","sequence":"additional","affiliation":[{"name":"Universidad UTE, Facultad de Ciencias de la Salud Eugenio Espejo, Centro Asociado Cochrane Ecuador, Centro de Investigaci\u00f3n en Salud P\u00fablica y Epidemiolog\u00eda Cl\u00ednica (CISPEC); Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J","family":"Riera Lizardo","sequence":"additional","affiliation":[{"name":"C\u00e1tedra Rectoral de Medicina Basada en la Evidencia; Universidad de Carabobo; Valencia Venezuela"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Nicola","sequence":"additional","affiliation":[{"name":"Universidad UTE, Facultad de Ciencias de la Salud Eugenio Espejo, Centro Asociado Cochrane Ecuador, Centro de Investigaci\u00f3n en Salud P\u00fablica y Epidemiolog\u00eda Cl\u00ednica (CISPEC); Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Elena","family":"Mart\u00ed-Amarista","sequence":"additional","affiliation":[{"name":"Primary Care - Geriatrics; JenCare Senior Medical Center; Berwyn Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Correa-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Faculty of Medicine; Universidad Francisco de Vitoria; Madrid Spain"},{"name":"Hospital Pharmacy and Medical Devices Department; Hospital Central de la Defensa \"G\u00f3mez Ulla\" CSVE; Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0001|cit1","first-page":"A102","article-title":"Interleukin-1 blockade ameliorates left ventricular remodeling following st-segment elevation acute myocardial infarction - the VCU-ART pilot study","volume":"55","author":"Abbate","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.amjcard.2009.12.059","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study)","volume":"105","author":"Abbate","year":"2010","journal-title":"American Journal Cardiology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"E179","DOI":"10.1016\/S0735-1097(13)60180-1","article-title":"Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling following acute myocardial infarction: results of the VCU-ART2 pilot study","volume":"61","author":"Abbate","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1394-1400","DOI":"10.1016\/j.amjcard.2013.01.287","article-title":"Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction","volume":"111","author":"Abbate","year":"2013","journal-title":"American Journal of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/eurheartj\/ehz747.0069","article-title":"Effects of Interleukin-1 blockade with anakinra on cardiac function in ST-segment elevation acute myocardial infarction: results from the VCUART3 echocardiography study","volume":"40","author":"Abbate","year":"2019","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"e014941","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/clc.22988","article-title":"Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): a randomized, placebo-controlled, double-blinded, multicenter study","volume":"41","author":"Van Tassell","year":"2018","journal-title":"Clinical Cardiology"},{"issue":"9993","key":"10.1002\/14651858.CD014741.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study","volume":"10","author":"Valenzuela","year":"2016","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3904\/kjim.2017.159","article-title":"Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis","volume":"34","author":"Baek","year":"2019","journal-title":"Korean Journal of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaad.2011.07.034","article-title":"Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept","volume":"67","author":"Bagel","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1468-3083.2011.04394.x","article-title":"Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept","volume":"27","author":"Tyring","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/archinte.166.8.902","article-title":"Effects of etanercept in patients with the metabolic syndrome","volume":"166","author":"Bernstein","year":"2006","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.CIR.103.8.1044","article-title":"Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure","volume":"103","author":"Bozkurt","year":"2001","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"e001108","DOI":"10.1136\/openhrt-2019-001108","article-title":"Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)","volume":"6","author":"Anstensrud","year":"2019","journal-title":"Open Heart"},{"issue":"15","key":"10.1002\/14651858.CD014741.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"18","key":"10.1002\/14651858.CD014741.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"issue":"21","key":"10.1002\/14651858.CD014741.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","article-title":"Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial","volume":"84","author":"Butchart","year":"2015","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00296-017-3842-y","article-title":"Short-term application of tocilizumab during myocardial infarction (STAT-MI)","volume":"38","author":"Carroll","year":"2018","journal-title":"Rheumatology International"},{"issue":"16","key":"10.1002\/14651858.CD014741.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jacc.2016.07.768","article-title":"Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance","volume":"68","author":"Choudhury","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"issue":"25","key":"10.1002\/14651858.CD014741.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD014741.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Van Der Heijde","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD014741.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/ard.2004.035105","article-title":"Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks","volume":"64","author":"Davis","year":"2005","journal-title":"Annals of the Rheumatic Disease"},{"issue":"25","key":"10.1002\/14651858.CD014741.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","article-title":"Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5414\/CNP73431","article-title":"The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients","volume":"73","author":"Don","year":"2010","journal-title":"Clinical Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD014741.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1210\/jc.2018-00739","article-title":"IL-1 antagonism in men with metabolic syndrome and low testosterone: a randomized clinical trial","volume":"103","author":"Ebrahimi","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/jnnp.2004.054882","article-title":"A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients","volume":"76","author":"Emsley","year":"2005","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0031|cit31","unstructured":"Smith C Emsley H Drennan R Libetta C Hopkins S Rothwell N A randomized, double-blind, placebo-controlled pilot study to investigate the safety of interleukin-1 receptor antagonist in patients with acute stroke British Association of Stroke Physicians Annual Conference 2002"},{"issue":"18","key":"10.1002\/14651858.CD014741.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor \u03b1","volume":"346","author":"Gorman","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Archives of Dermatology"},{"issue":"15","key":"10.1002\/14651858.CD014741.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2005.06510.x","article-title":"Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial","volume":"152","author":"Feldman","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10038","key":"10.1002\/14651858.CD014741.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0038|cit38","first-page":"242015","article-title":"Preliminary safety and efficacy data from the ongoing Fasscinate trial of subcutaneous tocilizumab in adults with systemic sclerosis","volume":"18","author":"Khanna","year":"2015","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD014741.pub2-BIB0039|cit39","first-page":"S3862014","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis: week 24 data from a phase 2\/3 trial","volume":"66","author":"Khanna","year":"2014","journal-title":"Arthritis and Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"e015628","DOI":"10.1161\/JAHA.119.015628","article-title":"Novel insights into the effects of interleukin 6 antagonism in non-ST-segment-elevation myocardial infarction employing the SOMAscan proteomics platform","volume":"9","author":"George","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"e001492","DOI":"10.1136\/openhrt-2020-001492","article-title":"Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction","volume":"8","author":"Helseth","year":"2021","journal-title":"Open Heart"},{"issue":"19","key":"10.1002\/14651858.CD014741.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/heartjnl-2016-310875","article-title":"Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction","volume":"103","author":"Holte","year":"2017","journal-title":"Heart"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014741.pub2-BIB0044|cit44","first-page":"672","article-title":"The impact of the interleukin 6 receptor antagonist tocilizumab on mircovascular dysfunction after nonSt elevation myocardial infarction assessed by coronary flow reserve from a randomized study","volume":"16","author":"Holte","year":"2015","journal-title":"European Heart Journal Cardiovascular Imaging"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0045|cit45","first-page":"27","article-title":"The interleukin-6 receptor antagonist tocilizumab reduces inflammation and myocardial damage in non-ST elevation myocardial infarction - a randomized, double-blind, placebo controlled study","volume":"36","author":"Kleveland","year":"2015","journal-title":"European Heart Journal"},{"issue":"30","key":"10.1002\/14651858.CD014741.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-STelevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2018.04.136","article-title":"Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1\u00df in non-ST-elevation myocardial infarction","volume":"271","author":"Kleveland","year":"2018","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.3389\/fimmu.2018.02035","article-title":"IL-6 receptor inhibition by tocilizumab attenuated expression of C5a receptor 1 and 2 in non-ST-elevation myocardial infarction","volume":"9","author":"Orrem","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"e000765","DOI":"10.1136\/openhrt-2017-000765","article-title":"Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction","volume":"5","author":"Ueland","year":"2018","journal-title":"Open Heart"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Research and Therapy"},{"issue":"7","key":"10.1002\/14651858.CD014741.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"e008197","DOI":"10.1161\/CIRCEP.119.008197","article-title":"Canakinumab after electrical cardioversion in patients with persistent atrial fibrillation: a pilot randomized trial","volume":"13","author":"Krisai","year":"2020","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"issue":"21","key":"10.1002\/14651858.CD014741.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"9227","key":"10.1002\/14651858.CD014741.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD014741.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"31.e1","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1186\/s13063-020-04783-4","article-title":"Interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (IMICA): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial","volume":"21","author":"Meyer","year":"2020","journal-title":"Trials"},{"issue":"19","key":"10.1002\/14651858.CD014741.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.053318","article-title":"Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (the IMICA Trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial","volume":"143","author":"Meyer","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0058|cit58","first-page":"57","article-title":"Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study","volume":"95","author":"Micali","year":"2015","journal-title":"2015"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1745-6215-9-8","article-title":"Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (the MRC-ILA-HEART Study)","volume":"9","author":"Crossman","year":"2008","journal-title":"Trials"},{"issue":"22","key":"10.1002\/14651858.CD014741.pub2-BIB0060|cit60","first-page":"A14792","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-st elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"128","author":"Morton","year":"2013","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1136\/heartjnl-2011-300198.15","article-title":"Investigation of IL-1 inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA Heart Study)","volume":"97","author":"Morton","year":"2011","journal-title":"Heart"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"European Heart Journal"},{"issue":"18","key":"10.1002\/14651858.CD014741.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/heartjnl-2013-303648","article-title":"Cardiovascular effects of tumour necrosis factor \u03b1 antagonism in patients with acute myocardial infarction: a first in human study","volume":"99","author":"Padfield","year":"2013","journal-title":"Heart"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0064|cit64","first-page":"A102","article-title":"Cardiovascular effects of tumour necrosis factor alpha antagonism in patients with acute myocardial infarction","volume":"55","author":"Padfield","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"A27","DOI":"10.1136\/hrt.2010.195958.19","article-title":"Cardiovascular effects of tumour necrosis effects of tumour necrosis factor alpha in patients with acute myocardial infarction","volume":"96","author":"Padfield","year":"2010","journal-title":"Heart"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/13543784.2020.1709822","article-title":"Phase I\/II parallel double-blind randomized controlled clinical trial of perispinal etanercept for chronic stroke: improved mobility and pain alleviation","volume":"29","author":"Ralph","year":"2020","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"13","key":"10.1002\/14651858.CD014741.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1594\u20131602","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"13","key":"10.1002\/14651858.CD014741.pub2-BIB0070|cit70","first-page":"1594\u20131602","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL)","volume":"109","author":"Mann","journal-title":"Circulation"},{"issue":"23","key":"10.1002\/14651858.CD014741.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"E1539","DOI":"10.1016\/S0735-1097(12)61540-X","article-title":"Effects of interleukin-1s inhibition with canakinumab on IL-6, fibrinogen, and HSCRP: a randomized placebo controlled trial","volume":"59","author":"Ridker","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"issue":"21","key":"10.1002\/14651858.CD014741.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes","volume":"71","author":"Everett","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0075|cit75","first-page":"A16242","article-title":"Anti-inflammatory therapy with canakinumab and reduction in total cardiovascular events","volume":"138","author":"Everett","year":"2018","journal-title":"Circulation"},{"issue":"14","key":"10.1002\/14651858.CD014741.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.jacc.2020.08.011","article-title":"Inhibition of interleukin-1 beta and reduction in atherothrombotic cardiovascular events in the CANTOS trial","volume":"76","author":"Everett","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0077|cit77","first-page":"A14380","article-title":"The effect of canakinumab on the rates of non-ST-segment elevation and ST-segment elevation myocardial infarctions","volume":"138","author":"Lang","year":"2018","journal-title":"Circulation"},{"issue":"38","key":"10.1002\/14651858.CD014741.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"European Heart Journal"},{"issue":"10118","key":"10.1002\/14651858.CD014741.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"issue":"21","key":"10.1002\/14651858.CD014741.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2405-14","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"10105","key":"10.1002\/14651858.CD014741.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"issue":"23","key":"10.1002\/14651858.CD014741.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"597-605","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"American Heart Journal"},{"issue":"46","key":"10.1002\/14651858.CD014741.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.119.13642","article-title":"Effects of interleukin-1\u03b2 inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS","volume":"75","author":"Rothman","year":"2020","journal-title":"Hypertension"},{"issue":"7","key":"10.1002\/14651858.CD014741.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"509","DOI":"10.7326\/M20-0527","article-title":"Effects of interleukin-1\u03b2 inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Schieker","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"535","DOI":"10.7326\/M18-1167","article-title":"Relationship of interleukin-1\u03b2 blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial","volume":"169","author":"Solomon","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.amjcard.2018.07.002","article-title":"Usefulness of canakinumab to improve exercise capacity in patients with long-term systolic heart failure and elevated C-reactive protein","volume":"122","author":"Trankle","year":"2018","journal-title":"American Journal of Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/M19-2945","article-title":"Effects of interleukin-1\u03b2 inhibition on incident anemia: exploratory analyses from a randomized trial","volume":"172","author":"Vallurupalli","year":"2020","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"A11","DOI":"10.1161\/atvb.37.suppl_1.11","article-title":"Effects of canakinumab in patients with peripheral artery disease","volume":"37","author":"Russell","year":"2017","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/1358863X19859072","article-title":"A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease","volume":"24","author":"Russell","year":"2019","journal-title":"Vascular Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0094|cit94","first-page":"481","article-title":"A randomised, placebo-controlled phase 2 trial of subcutaneous interleukin- 1 receptor antagonist in acute ischaemic stroke (SCIL-Stroke)","volume":"2","author":"Smith","year":"2017","journal-title":"European Stroke Journal"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0095|cit95","unstructured":"Smith C Hulme S Parry-Jones A Hopkins S Vail A Allan S A randomised, placebo-controlled phase II trial of subcutaneous interleukin-1 receptor antagonist in patients with acute ischaemic stroke (SCIL-STROKE) 9th UK Stroke Forum Conference 2014 57 8"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/STROKEAHA.118.020750","article-title":"SCIL-STROKE (Subcutaneous interleukin-1 receptor antagonist in ischemic stroke): a randomized controlled phase 2 trial","volume":"49","author":"Smith","year":"2018","journal-title":"Stroke"},{"issue":"9617","key":"10.1002\/14651858.CD014741.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0098|cit98","first-page":"E146\u2013E50","article-title":"TNF-\u03b1 antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome","volume":"96","author":"Stanley","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2010.04.014","article-title":"Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial","volume":"59","author":"Torii","year":"2010","journal-title":"Journal of Dermatological Science"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Archives of Dermatology"},{"issue":"9504","key":"10.1002\/14651858.CD014741.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(05)67763-X","article-title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","volume":"367","author":"Tyring","year":"2006","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0102|cit102","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension","volume":"159","author":"Van de Kerkhof","year":"2008","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kem069","article-title":"Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly","volume":"46","author":"Braun","year":"2007","journal-title":"Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/ard.2006.056747","article-title":"Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis","volume":"65","author":"Van der Heijde","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/FJC.0000000000000378","article-title":"Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study","volume":"67","author":"Van Tassell","year":"2016","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD014741.pub2-BIB0106|cit106","first-page":"A16959","article-title":"Interleukin-1 blockade in acute decompensated systolic heart failure: results of the Anakinra in Decompensated Heart Failure pilot study","volume":"132","author":"Van Tassell","year":"2015","journal-title":"Circulation"},{"issue":"18","key":"10.1002\/14651858.CD014741.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/j.cardfail.2016.06.093","article-title":"Relationship between plasma biomarkers and response to IL-1 blockade in acute decompensated heart failure","volume":"22","author":"Buckley","year":"2016","journal-title":"Journal of Cardiac Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0108|cit108","first-page":"A13404","article-title":"Interleukin1 is a critical mediator of systemic inflammation in patients with heart failure and chronic kidney disease: a post-hoc substudy of the Recently Decompensated Heart Failure Anakinra remodeling trial","volume":"138","author":"Buckley","year":"2018","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2022.03.026","article-title":"Patient perceptions of exertion and dyspnea with interleukin-1 blockade in patients with recently decompensated systolic heart failure","volume":"174","author":"Mihalick","year":"2022","journal-title":"American Journal of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD014741.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"e004373","DOI":"10.1161\/CIRCHEARTFAILURE.117.004373","article-title":"Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial)","volume":"10","author":"Van Tassell","year":"2017","journal-title":"Circulation. Heart Failure"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"A968","DOI":"10.1016\/S0735-1097(18)31509-2","article-title":"Interleukin-1 blockade reduces patient perceptions of exertion and dyspnea among patients with recently decompensated systolic heart failure: a subgroup analysis of the REDHART trial","volume":"71","author":"Van Tassell","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"10.1002\/14651858.CD014741.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0735-1097(18)31410-4","article-title":"Interleukin-1 blockade reduces NT-PROBNP serum levels in patients with stable heart failure with preserved ejection fraction","volume":"71","author":"Trankle","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014741.pub2-BIB0113|cit113","first-page":"A17709","article-title":"Interleukin1 blockade in heart failure with preserved ejection fraction: the Diastolic Heart Failure Anakinra Response Trial 2 (DHART2)","volume":"136","author":"Van Tassell","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD014741.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/clc.22719","article-title":"Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2)","volume":"40","author":"Van Tassell","year":"2017","journal-title":"Clinical Cardiology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"e005036","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circulation. Heart Failure"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology"},{"issue":"10031","key":"10.1002\/14651858.CD014741.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD014741.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/kem033","article-title":"A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases","volume":"46","author":"Weisman","year":"2007","journal-title":"Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/ard.2006.058339","article-title":"Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial","volume":"66","author":"Kavanaugh","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1468-3083.2011.03984.x","article-title":"Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study","volume":"25","author":"Bissonnette","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"9271","key":"10.1002\/14651858.CD014741.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Martinez-Taboada","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9494","key":"10.1002\/14651858.CD014741.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","article-title":"Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Gottlieb","year":"2011","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/23969873231185208","article-title":"Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage: BLOcking the Cytokine IL-1 in ICH (BLOC-ICH)","volume":"8","author":"Parry-Jones","year":"2023","journal-title":"European Stroke Journal"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Strober","year":"2011","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0129|cit129","unstructured":"Can IL-1ra reduce inflammation and improve clinical outcome following aneurysmal SAH? www.isrctn.com\/ISRCTN12961797"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.acvd.2023.07.004","article-title":"Rationale and design of the ARAMIS trial: anakinra versus placebo, a double blind randomized controlled trial for the treatment of acute myocarditis","volume":"116","author":"Kerneis","year":"2023","journal-title":"Archives of Cardiovascular Disease"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0131|cit131","unstructured":"Infliximab therapy in patients with refractory polymyalgia rheumatica: a double blind placebo controlled trial clinicaltrials.gov\/ct2\/show\/NCT01423591"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0132|cit132","unstructured":"Randomized, controlled, double-blind study of anakinra against placebo in addition to steroids in giant gell arteritis clinicaltrials.gov\/ct2\/show\/NCT02902731"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0133|cit133","unstructured":"Targeting inflammation and alloimmunity in heart transplant recipients With tocilizumab (RTB-004) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03644667"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"106731","DOI":"10.1016\/j.cct.2022.106731","article-title":"Heart failure clinical trial enrollment at a rural satellite hospital","volume":"115","author":"Sedhai","year":"2022","journal-title":"Contemporary Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12967-022-03466-9","article-title":"Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study","volume":"20","author":"Van Tassell","year":"2022","journal-title":"Journal of Translational Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12967-021-03130-8","article-title":"Interleukin-1 blockade in cardiac sarcoidosis: study design of the multimodality assessment of granulomas in cardiac sarcoidosis: Anakinra Randomized Trial (MAGiC-ART)","volume":"19","author":"Kron","year":"2021","journal-title":"Journal of Translational Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0137|cit137","unstructured":"Interleukin-1 blockade in acute myocardial infarction to prevent heart failure (Virginia-ART4) clinicaltrials.gov\/ct2\/show\/NCT05177822"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0138|cit138","unstructured":"Interleukin-1 blockade in acute myocardial infarction to prevent heart failure: the Virginia-Anakinra Remodeling Trial 4 clinicaltrials.gov\/ct2\/show\/NCT05177822"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD014741.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"195S","DOI":"10.1016\/0197-2456(89)90058-5","article-title":"Quality of life assessment in clinical trials: methodologic issues","volume":"10","author":"Aaronson","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0140|cit140","volume-title":"Basic Immunology. Functions and Disorders of the Immune System","author":"Abbas","year":"2020"},{"issue":"9","key":"10.1002\/14651858.CD014741.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the Inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circulation Research"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"e014941","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-segment-elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-immunol-042617-053104","article-title":"The emerging role of B lymphocytes in cardiovascular disease","volume":"38","author":"Adamo","year":"2020","journal-title":"Annual Review of Immunology"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3899\/jrheum.140861","article-title":"Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis","volume":"42","author":"Adlan","year":"2015","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/ATVBAHA.110.207415","article-title":"Recent advances on the role of cytokines in atherosclerosis","volume":"31","author":"Ait-Oufella","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/ATVBAHA.119.311998","article-title":"Anticytokine immune therapy and atherothrombotic cardiovascular risk","volume":"39","author":"Ait-Oufella","year":"2019","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"11","key":"10.1002\/14651858.CD014741.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11883-020-00883-3","article-title":"Targeting inflammation to reduce residual cardiovascular risk","volume":"22","author":"Ajala","year":"2020","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0149|cit149","doi-asserted-by":"crossref","unstructured":"Alexander RW Inflammation and coronary artery disease New England Journal of Medicine 1994 331 7 468 9 8035844","DOI":"10.1056\/NEJM199408183310709"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"550\u201371","DOI":"10.1038\/s44161-023-00278-y","article-title":"Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis","volume":"2","author":"Amadori","year":"2023","journal-title":"Nature Cardiovascular Research"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"7454","key":"10.1002\/14651858.CD014741.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10741-018-9716-x","article-title":"Role of cytokines and inflammation in heart function during health and disease","volume":"23","author":"Bartekova","year":"2018","journal-title":"Heart Failure Reviews"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11897-020-00476-w","article-title":"Evidence of clonal hematopoiesis and risk of heart failure","volume":"17","author":"Bazeley","year":"2020","journal-title":"Current Heart Failure Reports"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/jrsm.1297","article-title":"Methods for evidence synthesis in the case of very few studies","volume":"9","author":"Bender","year":"2018","journal-title":"Research Synthesis Methods"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics - 2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0158|cit158","doi-asserted-by":"crossref","DOI":"10.1002\/0470863641","volume-title":"Selection Bias and Covariate Imbalances in Randomized Clinical Trials","author":"Berger","year":"2005"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"adv508","DOI":"10.2340\/actadv.v103.5087","article-title":"Cardiovascular screening practices and statin prescription habits in patients with psoriasis among dermatologists, rheumatologists and primary care physicians","volume":"103","author":"Berna-Rico","year":"2023","journal-title":"Acta Dermato-Venereologica"},{"issue":"18","key":"10.1002\/14651858.CD014741.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1161\/CIRCULATIONAHA.109.918417","article-title":"Inflammation in peripheral artery disease.","volume":"122","author":"Brevetti","year":"2010","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10741-016-9533-z","article-title":"The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure","volume":"21","author":"Briasoulis","year":"2016","journal-title":"Heart Failure Reviews"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40259-018-0274-5","article-title":"Interleukin-1 blockade in cardiovascular diseases: from bench to bedside","volume":"32","author":"Buckley","year":"2018","journal-title":"BioDrugs"},{"issue":"22","key":"10.1002\/14651858.CD014741.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT-Outcomes 2022 Extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD014741.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00003246-199907000-00018","article-title":"Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function","volume":"27","author":"Cain","year":"1999","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"598549","DOI":"10.3389\/fphar.2021.598549","article-title":"Inflammation as a risk factor in cardiotoxicity: an important consideration for screening during drug development","volume":"12","author":"Campana","year":"2021","journal-title":"Frontiers in Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14397595.2018.1427457","article-title":"Tocilizumab in the treatment of myocardial infarction","volume":"28","author":"Carroll","year":"2018","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Frontiers in Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/eb-2014-101967","article-title":"A hands-on practical tutorial on performing meta-analysis with Stata","volume":"17","author":"Chaimani","year":"2014","journal-title":"Evidence-based Mental Health"},{"issue":"9683","key":"10.1002\/14651858.CD014741.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(09)60329-9","article-title":"Avoidable waste in the production and reporting of research evidence","volume":"374","author":"Chalmers","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.mehy.2013.06.016","article-title":"Pyroptosis: an inflammatory cell death implicates in atherosclerosis","volume":"81","author":"Chang","year":"2013","journal-title":"Medical Hypotheses"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"109751","DOI":"10.1016\/j.cellsig.2020.109751","article-title":"Extracellular vesicle signalling in atherosclerosis","volume":"75","author":"Charla","year":"2020","journal-title":"Cellular Signalling"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3389\/fphys.2020.01113","article-title":"The role of cardiac macrophage and cytokines on ventricular arrhythmias","volume":"11","author":"Chen","year":"2020","journal-title":"Frontiers in Physiology"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/cells10040881","article-title":"Cardiac dysfunction in rheumatoid arthritis: the role of inflammation","volume":"10","author":"Chen","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-97-5-672","article-title":"Polymyalgia rheumatica: a 10-year epidemiologic and clinical study","volume":"97","author":"Chuang","year":"1982","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1745-6215-8-39","article-title":"Standardising outcomes for clinical trials and systematic reviews","volume":"8","author":"Clarke","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0178|cit178","first-page":"165","article-title":"Update on the use of etanercept across a spectrum of rheumatoid disorders","volume":"2","author":"Combe","year":"2008","journal-title":"Biologics: Targets and Therapy"},{"issue":"10354","key":"10.1002\/14651858.CD014741.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fphar.2017.00293","article-title":"A brief history of IL-1 and IL-1 Ra in rheumatology","volume":"8","author":"Dayer","year":"2017","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"5843958","DOI":"10.1155\/2020\/5843958","article-title":"Interleukin-8 in hyperlipidemia and coronary heart disease in Thai patients taking statin cholesterol-lowering medication while undergoing coronary artery bypass grafting treatment","volume":"2020","author":"Dechkhajorn","year":"2020","journal-title":"Scientifica"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/9781119536604.ch10","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks","year":"2019"},{"issue":"16","key":"10.1002\/14651858.CD014741.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/sim.6909","article-title":"Type-II generalized family-wise error rate formulas with application to sample size determination","volume":"35","author":"Delorme","year":"2016","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1381612826666200717090334","article-title":"High sensitivity C-reactive protein (hsCRP) and its implications in cardiovascular outcomes","volume":"27","author":"Denegri","year":"2021","journal-title":"Current Pharmaceutical Design"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","article-title":"Anti-inflammatory agents: present and future","volume":"140","author":"Dinarello","year":"2010","journal-title":"Cell"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","article-title":"Treating inflammation by blocking interleukin-1 in humans","volume":"25","author":"Dinarello","year":"2013","journal-title":"Seminars in Immunology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jcph.938","article-title":"Core entrustable professional activities in clinical pharmacology for entering residency: biologics","volume":"57","author":"Donnenberg","year":"2017","journal-title":"Journal of Clinical Pharmacology"},{"issue":"9822","key":"10.1002\/14651858.CD014741.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis","volume":"379","author":"Dudbridge","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.semvascsurg.2021.02.005","article-title":"Epidemiology of peripheral artery disease","volume":"34","author":"Eid","year":"2021","journal-title":"Seminars in Vascular Surgery"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0190|cit190","unstructured":"European Medicines Agency Kineret (anakinra) www.ema.europa.eu\/en\/documents\/overview\/kineret-epar-medicine-overview_en.pdf"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0191|cit191","unstructured":"European Medicines Agency Ilaris (Canakinumab) www.ema.europa.eu\/en\/documents\/product-information\/ilaris-epar-product-information_en.pdf 1 93"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0192|cit192","unstructured":"European Medicines Agency Roactemra (tocilizumab) www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf 1 175"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0193|cit193","unstructured":"European Medicines Agency Erelzi (etanercept) www.ema.europa.eu\/en\/documents\/product-information\/erelzi-epar-product-information_en.pdf 1 89"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0194|cit194","unstructured":"European Medicines Agency Remsima (infliximab) www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf 1 148"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"12246","DOI":"10.1111\/jcmm.15880","article-title":"Recent advances on the roles of LncRNAs in cardiovascular disease","volume":"24","author":"Fang","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0197|cit197","first-page":"e32308","article-title":"Increased risk of cardiovascular diseases in rheumatoid arthritis: a systematic review","volume":"14","author":"Farhat","year":"2022","journal-title":"Cureus"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0198|cit198","unstructured":"CDER therapeutic biologic products www.fda.gov\/media\/76650\/download 1 78"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0199|cit199","unstructured":"Clinical review www.fda.gov\/media\/80457\/download"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0200|cit200","unstructured":"Potential signals of serious risks\/new safety information identified from the FDA adverse event reporting system (FAERS) fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/january-march-2018-potential-signals-serious-risksnew-safety-information-identified-fda-adverse"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0201|cit201","unstructured":"Medication guide. ILARIS (i-LAHR-us) (canakinumab) injection for subcutaneous use www.fda.gov\/media\/86042\/download"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0202|cit202","unstructured":"Drugs@FDA Glossary of Terms www.fda.gov\/drugs\/drug-approvals-and-databases\/drugsfda-glossary-terms"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0891-4222(94)00028-8","article-title":"Quality of life: its definition and measurement","volume":"16","author":"Felce","year":"1995","journal-title":"Research in Developmental Disabilities"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1387\/theoria.19329","article-title":"Scientific ignorance: probing the limits of scientific research and knowledge production","volume":"34","author":"Fern\u00e1ndez Pinto","year":"2019","journal-title":"Theoria"},{"issue":"25","key":"10.1002\/14651858.CD014741.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1161\/hc5001.101749","article-title":"Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure","volume":"104","author":"Fichtlscherer","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/1570161117666190619143842","article-title":"Cardiovascular risk in rheumatoid arthritis and mechanistic links: from pathophysiology to treatment","volume":"18","author":"Fragoulis","year":"2020","journal-title":"Current Vascular Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jclinepi.2010.09.016","article-title":"Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods","volume":"64","author":"Friedrich","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9165","key":"10.1002\/14651858.CD014741.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S0140-6736(99)01163-0","article-title":"From effect size to number needed to treat","volume":"353","author":"Furukawa","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"e19070","DOI":"10.1371\/journal.pone.0019070","article-title":"How to obtain NNT from Cohen's d: comparison of two methods","volume":"6","author":"Furukawa","year":"2011","journal-title":"PloS One"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jclinepi.2004.09.013","article-title":"Uncertainty method improved on best-worst case analysis in a binary meta-analysis","volume":"58","author":"Gamble","year":"2005","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0211|cit211","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-1005-9","volume-title":"Encyclopedia of Behavioral Medicine","author":"Gellman","year":"2013"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5114\/kitp.2016.58974","article-title":"Tools for assessing quality of life in cardiology and cardiac surgery","volume":"13","author":"Gierlaszy\u0144ska","year":"2016","journal-title":"Kardiochirurgia i Torakochirurgia Polska\/Polish Journal of Thoracic and Cardiovascular Surgery"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2017.00123","article-title":"The P2X7 receptor-interleukin-1 liaison","volume":"8","author":"Giuliani","year":"2017","journal-title":"Frontiers in Pharmacology"},{"issue":"22","key":"10.1002\/14651858.CD014741.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"12109","DOI":"10.3390\/ijms222212109","article-title":"Emerging anti-atherosclerotic therapies","volume":"22","author":"Gluba-Brz\u00f3zka","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0215|cit215","unstructured":"GRADEpro McMaster University (developed by Evidence Prime) 2024"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0216|cit216","first-page":"903","volume-title":"Comprehensive Clinical Nephrology","author":"Grams","year":"2019"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"i1981","DOI":"10.1136\/bmj.i1981","article-title":"Sparse data bias: a problem hiding in plain sight","volume":"352","author":"Greenland","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/bjs.6558","article-title":"Assessment of risk of bias in randomized clinical trials in surgery","volume":"96","author":"Gurusamy","year":"2009","journal-title":"British Journal of Surgery"},{"issue":"7651","key":"10.1002\/14651858.CD014741.pub2-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10557-020-07071-0","article-title":"Inflammatory cytokines and chemokines as therapeutic targets in heart failure","volume":"34","author":"Hanna","year":"2020","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s40257-019-00440-y","article-title":"Autoinflammatory disorders: a review and update on pathogenesis and treatment","volume":"20","author":"Havnaer","year":"2019","journal-title":"American Journal of Clinical Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1161\/ATVBAHA.117.309307","article-title":"Circulating levels of interleukin 1-receptor antagonist and risk of cardiovascular disease: meta-analysis of six population-based cohorts","volume":"37","author":"Herder","year":"2017","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11906-019-0907-1","article-title":"Innate and innate-like immune system in hypertension and vascular injury","volume":"21","author":"Higaki","year":"2019","journal-title":"Current Hypertension Reports"},{"issue":"7414","key":"10.1002\/14651858.CD014741.pub2-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0226|cit226","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2019"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"j2998","DOI":"10.1136\/bmj.j2998","article-title":"Enhancing the usability of systematic reviews by improving the consideration and description of interventions","volume":"358","author":"Hoffmann","year":"2017","journal-title":"BMJ"},{"issue":"7211","key":"10.1002\/14651858.CD014741.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","article-title":"What is meant by intention to treat analysis? Survey of published randomised controlled trials","volume":"319","author":"Hollis","year":"1999","journal-title":"BMJ"},{"issue":"19","key":"10.1002\/14651858.CD014741.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/heartjnl-2016-310875","article-title":"Effect of interleukin-6 inhibition on coronary microvascular and endothelial function in myocardial infarction","volume":"103","author":"Holte","year":"2017","journal-title":"Heart"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/0002-9343(87)90450-5","article-title":"Complexity and contradiction in clinical trial research","volume":"82","author":"Howrwitz","year":"1987","journal-title":"American Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3928\/02793695-20110705-06","article-title":"What you see depends on where you're looking and how you look at it: publication bias and outcome reporting bias","volume":"49","author":"Howland","year":"2011","journal-title":"Journal of Psychosocial Nursing and Mental Health Services"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0233|cit233","unstructured":"International Committee of Medical Journal Editors Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication www.icmje.org\/recommendations\/archives\/2006_urm.pdf"},{"issue":"1A","key":"10.1002\/14651858.CD014741.pub2-BIB0234|cit234","first-page":"S3","article-title":"The pathology of atherosclerosis: plaque development and plaque responses to medical treatment","volume":"122","year":"2009","journal-title":"American Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD014741.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","article-title":"Plea for routinely presenting prediction intervals in meta-analysis","volume":"6","author":"IntHout","year":"2016","journal-title":"BMJ Open"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/EDE.0b013e31818131e7","article-title":"Why most discovered true associations are inflated","volume":"19","author":"Ioannidis","year":"2008","journal-title":"Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.seminhematol.2008.04.010","article-title":"Perfect study, poor evidence: interpretation of biases preceding study design","volume":"45","author":"Ioannidis","year":"2008","journal-title":"Seminars in Hematology"},{"issue":"19","key":"10.1002\/14651858.CD014741.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","article-title":"Adverse events in randomized trials: neglected, restricted, distorted, and silenced","volume":"169","author":"Ioannidis","year":"2009","journal-title":"Archives of Internal Medicine"},{"issue":"3-4","key":"10.1002\/14651858.CD014741.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jrsm.19","article-title":"Meta-research: the art of getting it wrong","volume":"1","author":"Ioannidis","year":"2010","journal-title":"Research Synthesis Methods"},{"issue":"9912","key":"10.1002\/14651858.CD014741.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0140-6736(13)62227-8","article-title":"Increasing value and reducing waste in research design, conduct, and analysis","volume":"383","author":"Ioannidis","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1017\/S0140525X21000054","article-title":"Science with or without statistics: discover-generalize-replicate? Discover-replicate-generalize?","volume":"45","author":"Ioannidis","year":"2022","journal-title":"Behavioral and Brain Sciences"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.intimp.2018.12.028","article-title":"Role of pyroptosis in cardiovascular diseases","volume":"67","author":"Jia","year":"2019","journal-title":"International Immunopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1503\/cmaj.150430","article-title":"Do clinicians understand the size of treatment effects? A randomized survey across 8 countries","volume":"188","author":"Johnston","year":"2016","journal-title":"Canadian Medical Association Journal"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/HCO.0000000000000726","article-title":"Genetics of age-related clonal hematopoiesis and atherosclerotic cardiovascular disease","volume":"35","author":"Jung","year":"2020","journal-title":"Current Opinion in Cardiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jclinepi.2023.04.005","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials","volume":"158","author":"Junqueira","year":"2023","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0247|cit247","volume-title":"Concise Dictionary of Biomedicine and Molecular Biology","year":"2001"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00281-015-0501-9","article-title":"Regulating against the dysregulation: new treatment options in autoinflammation","volume":"37","author":"Kallinich","year":"2015","journal-title":"Seminars in Immunopathology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.atherosclerosis.2018.02.036","article-title":"The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity","volume":"271","author":"Kasselman","year":"2018","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/acr.22929","article-title":"Cost-effectiveness of cardiovascular screening in patients with rheumatoid arthritis","volume":"69","author":"Kievit","year":"2017","journal-title":"Arthritis Care and Research"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2302\/kjm.68-007-ABST","article-title":"Discovery of IL-6 and development of anti-IL-6R antibody","volume":"68","author":"Kishimoto","year":"2019","journal-title":"Keio Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/cvr\/cvn120","article-title":"Cytokines and atherosclerosis: a comprehensive review of studies in mice","volume":"79","author":"Kleemann","year":"2008","journal-title":"Cardiovascular Research"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2018.04.136","article-title":"Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1\u03b2 in non-ST-elevation myocardial infarction","volume":"271","author":"Kleveland","year":"2018","journal-title":"International Journal of Cardiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0255|cit255","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-03323-1","volume-title":"From Basic to Clinical Immunology","author":"Klimov","year":"2019"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3899\/jrheum.131540","article-title":"Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 Tesla Cardiac Magnetic Resonance Imaging","volume":"41","author":"Kobayashi","year":"2014","journal-title":"Journal of Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3899\/jrheum.180065","article-title":"Heart rate-corrected QT interval duration in rheumatoid arthritis and its reduction with treatment with the interleukin 6 inhibitor tocilizumab","volume":"45","author":"Kobayashi","year":"2018","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0258|cit258","first-page":"356","article-title":"Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables","volume":"17","author":"Koller-Strametz","year":"1998","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"395\u2013407","DOI":"10.1177\/1536867X1001000307","article-title":"Metaan: random-effects meta-analysis","volume":"10","author":"Kontopantelis","year":"2010","journal-title":"Stata Journal"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-020-02275-z","article-title":"Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis","volume":"22","author":"Kwon","year":"2020","journal-title":"Arthritis Research and Therapy"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0261|cit261","volume-title":"The Dictionary of Cell and Molecular Biology","author":"Lackie","year":"2007"},{"issue":"26","key":"10.1002\/14651858.CD014741.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"2","author":"Lawler","year":"2020","journal-title":"European Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.thromres.2005.10.012","article-title":"Circulating CD40 ligand is elevated only in patients with more advanced symptomatic peripheral arterial diseases","volume":"118","author":"Lee","year":"2006","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0265|cit265","first-page":"67\u2013108","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2019"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0267|cit267","volume-title":"Cardiology Secrets","author":"Levine","year":"2018"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.2174\/1381612822666161230142931","article-title":"Inflammation: a novel therapeutic target\/direction in atherosclerosis","volume":"23","author":"Li","year":"2017","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0269|cit269","first-page":"109\u2013142","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Li","year":"2019"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tcm.2016.07.006","article-title":"Cardiovascular disease in patients with rheumatoid arthritis","volume":"27","author":"Liao","year":"2017","journal-title":"Trends in Cardiovascular Medicine"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jacc.2005.02.058","article-title":"Act local, act global: inflammation and the multiplicity of \"vulnerable\" coronary plaques","volume":"45","author":"Libby","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"18","key":"10.1002\/14651858.CD014741.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"17","key":"10.1002\/14651858.CD014741.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis","volume":"72","author":"Libby","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0274|cit274","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/cvr\/cvaa211","article-title":"Inflammation and cardiovascular diseases: lessons from seminal clinical trials","volume":"117","author":"Liberale","year":"2021","journal-title":"Cardiovascular Research"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41569-019-0323-x","article-title":"Anti-inflammatory therapy for secondary prevention after MI","volume":"17","author":"Lim","year":"2020","journal-title":"Nature Reviews. Cardiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3389\/fcell.2020.00692","article-title":"Mitochondrial contact sites in inflammation-induced cardiovascular disease","volume":"8","author":"Liu","year":"2020","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.idc.2020.02.003","article-title":"Infectious implications of interleukin-1, interleukin-6, and T helper type 2 inhibition","volume":"34","author":"Liu","year":"2020","journal-title":"Infectious Disease Clinics of North America"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0278|cit278","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-97622-8_1","volume-title":"Comprehensive Cardiovascular Medicine in the Primary Care Setting","author":"Maki","year":"2019"},{"issue":"13","key":"10.1002\/14651858.CD014741.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure results of the randomized etanercept worldwide evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1080\/09537104.2020.1817360","article-title":"Immunothrombosis and thromboinflammation in host defense and disease","volume":"32","author":"Martinod","year":"2020","journal-title":"Platelets"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0281|cit281","first-page":"9","volume-title":"Randomization, Masking, and Allocation Concealment","author":"Mart\u00ed-Carvajal","year":"2018"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0282|cit282","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015003","article-title":"Colchicine for the primary prevention of cardiovascular events","author":"Mart\u00ed-Carvajal","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00281-015-0497-1","article-title":"Broadening the definition of autoinflammation","volume":"37","author":"Masters","year":"2015","journal-title":"Seminars in Immunopathology"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2005.01.054","article-title":"Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction","volume":"45","author":"Mauriello","year":"2005","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","article-title":"Inflammation, immunity, and hypertensive end-organ damage","volume":"116","author":"McMaster","year":"2015","journal-title":"Circulation Research"},{"issue":"9 February","key":"10.1002\/14651858.CD014741.pub2-BIB0286|cit286","doi-asserted-by":"publisher","first-page":"100267","DOI":"10.1016\/j.ahjo.2023.100267","article-title":"Chronic rheumatologic disorders and cardiovascular disease risk in women","volume":"27","author":"Mehta","year":"2023","journal-title":"American Heart Journal Plus"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents - comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"issue":"18","key":"10.1002\/14651858.CD014741.pub2-BIB0288|cit288","doi-asserted-by":"crossref","first-page":"E6462","DOI":"10.3390\/ijms21186462","article-title":"Molecular basis of inflammation in the pathogenesis of cardiomyopathies","volume":"21","author":"Monda","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11883-017-0646-1","article-title":"The role of inflammation in cardiovascular outcome","volume":"19","author":"Montecucco","year":"2017","journal-title":"Current Atherosclerosis Reports"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0290|cit290","doi-asserted-by":"crossref","DOI":"10.1007\/3-540-29662-X","volume-title":"Rheumatology and Immunology Therapy. A to Z Essentials","author":"Moreland","year":"2004"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jjcc.2018.05.010","article-title":"Critical roles of inflammation in atherosclerosis","volume":"73","author":"Moriya","year":"2019","journal-title":"Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJMra1808137","article-title":"Acute infection and myocardial infarction","volume":"380","author":"Musher","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014741.pub2-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"4","DOI":"10.26442\/terarkh20189054-12","article-title":"Atherosclerosis: perspectives of anti-inflammatory therapy","volume":"90","author":"Nasonov","year":"2018","journal-title":"Terapevticheskii Arkhiv"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0294|cit294","unstructured":"National Cancer Institute Humanized monoclonal antibody www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/humanized-monoclonal-antibody (Dictionary of Cancer Terms)"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0295|cit295","unstructured":"National Cancer Institute Anakinra www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/anakinra (National Cancer Institute (NCI) Drug Dictionary)"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0296|cit296","unstructured":"National Cancer Institute Canakinumab www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/795723 (NCI Drug Dictionary)"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0297|cit297","unstructured":"National Cancer Institute Etanercept www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/etanercept (NCI Drug Dictionary)"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/jcm8081109","article-title":"Inflammation as a therapeutic target in atherosclerosis","volume":"8","author":"Nguyen","year":"2019","journal-title":"Journal of Clinical Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1160\/TH06-01-0007","article-title":"Prothrombotic activity is associated with the anatomical as well as the functional severity of peripheral arterial occlusive disease","volume":"95","author":"Nylaende","year":"2006","journal-title":"Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/1358863x06vm662oa","article-title":"Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease","volume":"11","author":"Nylaende","year":"2006","journal-title":"Vascular Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0301|cit301","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2020.07.027","article-title":"A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: clinical and therapeutic implications","volume":"309","author":"Oikonomou","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-7020-6896-6.00009-0","volume-title":"Clinical Immunology: Principles and Practice","author":"O\u2019Shea","year":"2019"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","article-title":"Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement","volume":"134","author":"Page","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0304|cit304","unstructured":"Pan A Gerriets V Etanercept https:\/\/www.statpearls.com\/ 31424836"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD014741.pub2-BIB0305|cit305","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1097\/MLR.0000000000001593","article-title":"Patient-centered approaches to transitional care research and implementation: overview and insights from patient-centered outcomes Research Institute's transitional care portfolio","volume":"59","author":"Parry","year":"2021","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fphar.2017.00363","article-title":"IL-1\u03b2 inhibition in cardiovascular complications associated to diabetes mellitus","volume":"8","author":"Peir\u00f3","year":"2017","journal-title":"Frontiers in Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.jclinepi.2010.12.012","article-title":"Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects","volume":"64","author":"Pereira","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0308|cit308","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0309|cit309","doi-asserted-by":"crossref","DOI":"10.1093\/acref\/9780199976720.001.0001","volume-title":"A Dictionary of Epidemiology","author":"Porta","year":"2014"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0310|cit310","first-page":"171","article-title":"Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update","volume":"131","author":"Prieto-Pe\u00f1a","year":"2021","journal-title":"Polish Archives of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD014741.pub2-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2459\/JCM.0000000000000974","article-title":"Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study","volume":"21","author":"Pugliese","year":"2020","journal-title":"Journal of Cardiovascular Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.07.014","article-title":"Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions","volume":"276","author":"Raggi","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fcvm.2018.00032","article-title":"Insights from pre-clinical and clinical studies on the role of innate inflammation in atherosclerosis regression","volume":"5","author":"Rahman","year":"2018","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1097\/HJH.0000000000002456","article-title":"Adaptive immune disorders in hypertension and heart failure: focusing on T-cell subset activation and clinical implications","volume":"38","author":"Rai","year":"2020","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0315|cit315","unstructured":"Review Manager Web (RevManWeb) Nordic Cochrane Centre 2019"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"9259646","DOI":"10.1155\/2016\/9259646","article-title":"Biologics for targeting inflammatory cytokines, clinical uses, and limitations","volume":"2016","author":"Rider","year":"2016","journal-title":"International Journal of Cell Biology"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis","volume":"124","author":"Ridker","year":"2019","journal-title":"Circulation Research"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"h2463","DOI":"10.1136\/bmj.h2463","article-title":"The knowledge system underpinning healthcare is not fit for purpose and must change","volume":"350","author":"Roberts","year":"2015","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD014741.pub2-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1253\/circj.CJ-14-0023","article-title":"Tumor necrosis factor - \u03b1 predicts response to cardiac resynchronization therapy in patients with chronic heart failure","volume":"78","author":"Rordorf","year":"2014","journal-title":"Circulation Journal"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis - an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/heartjnl-2018-314230","article-title":"Inflammation and atherosclerosis: what is on the horizon?","volume":"106","author":"Ruparelia","year":"2020","journal-title":"Heart"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0021-9150(96)05968-0","article-title":"Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall","volume":"127","author":"Rus","year":"1996","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jacbts.2017.07.001","article-title":"Failure to launch: targeting Inflammation in acute coronary syndromes","volume":"2","author":"Rymer","year":"2017","journal-title":"Journal of the American College of Cardiology. Basic to Translational Science"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1161\/CIRCRESAHA.118.313225","article-title":"CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease","volume":"123","author":"Sano","year":"2018","journal-title":"Circulation Research"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"issue":"9822","key":"10.1002\/14651858.CD014741.pub2-BIB0328|cit328","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.autrev.2018.12.009","article-title":"Systemic rheumatic diseases: from biological agents to small molecules","volume":"18","author":"Sarzi-Puttini","year":"2019","journal-title":"Autoinmmunity Reviews"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovic","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-1-0716-1566-9_5","article-title":"Performing meta-analyses with very few studies","volume":"2345","author":"Schulz","year":"2022","journal-title":"Methods in Molecular Biology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/9781119536604.ch14","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2019"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/0194599819852604","article-title":"Understanding the minimal clinically important difference (MCID) of patient-reported outcome measures","volume":"161","author":"Sedaghat","year":"2019","journal-title":"Otolaryngology Head and Neck Surgery"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.18901.1","article-title":"Inflammation in atherosclerotic cardiovascular disease","volume":"8","author":"Shah","year":"2019","journal-title":"F1000Research"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0335|cit335","volume-title":"Peripheral Vascular Disease in Primary Care","author":"Sharma","year":"2016"},{"issue":"9","key":"10.1002\/14651858.CD014741.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (Actemra)","volume":"13","author":"Sheppard","year":"2017","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"11","key":"10.1002\/14651858.CD014741.pub2-BIB0337|cit337","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012437","article-title":"Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)","author":"Singh","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal antibodies: a review","volume":"13","author":"Singh","year":"2018","journal-title":"Current Clinical Pharmacology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"i1446","DOI":"10.1136\/bmj.i1446","article-title":"The pursuit of ignorance","volume":"352","author":"Smith","year":"2016","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0340|cit340","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis - from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0341|cit341","doi-asserted-by":"crossref","DOI":"10.1002\/9780470750667","volume-title":"Peripheral Vascular Disease for Cardiologists. A Clinical Approach","author":"Spittel Jr","year":"2004"},{"issue":"9","key":"10.1002\/14651858.CD014741.pub2-BIB0342|cit342","first-page":"805","article-title":"Critical appraisal of contemporary clinical endpoint definitions in coronary intervention trials: a guidance document","volume":"12","author":"Spitzer","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0344|cit344","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"American Journal of Managed Care"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/ATVBAHA.116.308036","article-title":"2016 Russell Ross Memorial Lecture in Vascular Biology: molecular-cellular mechanisms in the progression of atherosclerosis","volume":"37","author":"Tabas","year":"2017","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"1-3","key":"10.1002\/14651858.CD014741.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2007.10.049","article-title":"Cytokines and anti-cytokines as therapeutics - an update","volume":"579","author":"Tayal","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0347|cit347","first-page":"248","volume-title":"Clinical Pharmacology","author":"Thornton","year":"2019"},{"issue":"22","key":"10.1002\/14651858.CD014741.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/eurheartj\/ehv759","article-title":"Inflammatory cytokines in atherosclerosis: current therapeutic approaches","volume":"37","author":"Tousoulis","year":"2016","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/ATVBAHA.114.303569","article-title":"Targeting B cells in atherosclerosis: closing the gap from bench to bedside","volume":"35","author":"Tsiantoulas","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"111309","DOI":"10.1016\/j.jclinepi.2024.111309","article-title":"Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements","volume":"169","author":"Tunn","year":"2024","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40263-013-0067-9","article-title":"Publication bias, with a focus on psychiatry: causes and solutions","volume":"27","author":"Turner","year":"2013","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000505099","article-title":"Interleukin-6: a masterplayer in the cytokine network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"e000765","DOI":"10.1136\/openhrt-2017-000765","article-title":"Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction","volume":"5","author":"Ueland","year":"2018","journal-title":"Open Heart"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/ATVBAHA.119.313064","article-title":"2019 Russell Ross Memorial Lecture in Vascular Biology: B lymphocyte-mediated protective immunity in atherosclerosis","volume":"40","author":"Upadhye","year":"2020","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"8","key":"10.1002\/14651858.CD014741.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"e0237072","DOI":"10.1371\/journal.pone.0237072","article-title":"Cardiovascular risk in persons at risk of developing rheumatoid arthritis","volume":"15","author":"Van Boheemen","year":"2020","journal-title":"PloS One"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0357|cit357","first-page":"EVIDoa2300003","article-title":"A new look at P values for randomized clinical trials","volume":"3","author":"Van Zwet","year":"2024","journal-title":"NEJM Evidence"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41423-020-00530-6","article-title":"Human immunology and immunotherapy: main achievements and challenges","volume":"18","author":"Varad\u00e9","year":"2020","journal-title":"Cellular and Molecular Immunology"},{"issue":"2","key":"10.1002\/14651858.CD014741.pub2-BIB0359|cit359","first-page":"132","article-title":"Eliminating bias in randomized controlled trials: importance of allocation concealment and masking","volume":"39","author":"Viera","year":"2005","journal-title":"Family Medicine"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0360|cit360","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/CIRCULATIONAHA.119.044282","article-title":"Secondary prevention for atherosclerotic cardiovascular disease comparing recent US and European guidelines on dyslipidemia","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0361|cit361","volume-title":"Introduction to Clinical Pharmacology","author":"Visovsky","year":"2019"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cca.2020.06.044","article-title":"Pyroptosis: a pro-inflammatory type of cell death in cardiovascular disease","volume":"510","author":"Wang","year":"2020","journal-title":"Clinica Chimica Acta"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"4904217","DOI":"10.1155\/2020\/4904217","article-title":"Immune and inflammation in acute coronary syndrome: molecular mechanisms and therapeutic implications","volume":"2020","author":"Wang","year":"2020","journal-title":"Journal of Immunology Research"},{"issue":"1","key":"10.1002\/14651858.CD014741.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12874-021-01228-7","article-title":"Using a distribution-based approach and systematic review methods to derive minimum clinically important differences","volume":"21","author":"Watt","year":"2021","journal-title":"BMC Medical Research Methodology"},{"issue":"7","key":"10.1002\/14651858.CD014741.pub2-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41584-023-00969-7","article-title":"Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease","volume":"19","author":"Weber","year":"2023","journal-title":"Nature Reviews. Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD014741.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/bcpt.13791","article-title":"Biases in reporting of adverse effects in clinical trials, and potential impact on safety assessments in systematic reviews and therapy guidelines","volume":"131","author":"Westergren","year":"2022","journal-title":"Basic and Clinical Pharmacology and Toxicology"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0367|cit367","unstructured":"Cardiovascular diseases www.who.int\/health-topics\/cardiovascular-diseases#tab=tab_1"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.23548","article-title":"Causes of death in rheumatoid arthritis: how do they compare to the general population?","volume":"70","author":"Widdifield","year":"2018","journal-title":"Arthritis Care and Research"},{"issue":"4","key":"10.1002\/14651858.CD014741.pub2-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.immuni.2019.03.007","article-title":"Cytokine circuits in cardiovascular disease","volume":"50","author":"Williams","year":"2019","journal-title":"Immunity"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0370|cit370","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cca.2017.11.005","article-title":"Pyroptosis and its relationship to atherosclerosis","volume":"476","author":"Xu","year":"2018","journal-title":"Clinica Chimica Acta"},{"key":"10.1002\/14651858.CD014741.pub2-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jclinepi.2023.03.027","article-title":"Presentation approaches for enhancing interpretability of patient-reported outcomes in meta-analyses: a systematic survey of Cochrane reviews","volume":"158","author":"Zeng","year":"2023","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD014741.pub2-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/aje\/kwad131","article-title":"Impact of allocation concealment and blinding in trials addressing treatments for COVID-19: a methods study","volume":"192","author":"Zeraatkar","year":"2023","journal-title":"American Journal of Epidemiology"},{"issue":"13","key":"10.1002\/14651858.CD014741.pub2-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jacc.2018.12.083","article-title":"Targeting the immune system in atherosclerosis","volume":"73","author":"Zhao","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD014741.pub2-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/ATVBAHA.111.224907","article-title":"Cell death, damage-associated molecular patterns, and sterile inflammation in cardiovascular disease","volume":"31","author":"Zheng","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"3","key":"10.1002\/14651858.CD014741.pub2-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1021\/acsptsci.9b00100","article-title":"The role of toll-like receptors in atherothrombotic cardiovascular disease","volume":"3","author":"Zhou","year":"2020","journal-title":"ACS Pharmacology and Translational Science"},{"issue":"9","key":"10.1002\/14651858.CD014741.pub2-BIB0376|cit376","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014741","article-title":"Interleukin-receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases","author":"Mart\u00ed-Carvajal","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T20:09:35Z","timestamp":1751227775000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014741.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":376,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014741.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}